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Summary
Periprosthetic fractures are becoming increasingly fre-
quent due to aging population and growing number of
total joint replacements involving joints different from
hip and knee, such as shoulder and elbow. The treat-
ment of these fractures still represents one of the ma-
jor challenges for the orthopedic surgeon. Despite all
efforts to understand and treat these patients, high rate
of failure and mortality are still reported. In this review,
the epidemiology of periprosthetic fractures, risk fac-
tors and results of surgical treatment are disclosed.
Moreover, we propose a treatment algorithm based on
the findings of the New Unified Classification System.
KEY WORDS: periprosthetic fractures; UCS classification; revision surgery; ana-
bolic drugs/bone healing.
Background
Periprosthetic fractures (PF) are considered fractures asso-
ciated with an orthopedic implant, whether a replacement
or internal fixation device. The global incidence of all types
of PF is increasing constantly due to the growing number of
primary joint arthroplasties and revision surgeries (1).
Moreover, patients who demand for arthroplasty are be-
coming older and more active due to the healthcare im-
provements. 
The total amount of PF is mainly determined by fractures about
hip and knee due to their marked predominance of procedures
compared to the other joints. However, the growth rates of
shoulder arthroplasties are becoming even higher than the
rates of hip and knee procedures (2). 
We therefore focused our review on fractures around hip,
knee and shoulder arthroplasty.
Epidemiology
Several studies in the literature have suggested rates of
postoperative PF after primary total hip arthroplasty (THA)
ranging from 0.1 to 18%, after total knee arthroplasty (TKA)
from 0.3 and 5.5% and after total shoulder arthroplasty
(TSA) from 0.5 to 3% (3).
Intraoperative fractures may be occult, in particular in ac-
etabulum after THA (4) and in supracondylar femur after
TKA (3). The rate of femoral intra-operative fractures is
around 1.7% for primary THA compared to 20-year postop-
erative fracture probability of 3.5% (5). Periprosthetic knee
fractures performing TKA are rare and the reported inci-
dence, ranging from 0.3% to 3.13%, may be under-estimat-
ed (6). In TSA the reported rate of intra-operative humeral
fracture is 1.2% and it represents the major complication
during humeral stem fixation (3, 5). 
Due to the increasing number of arthroplasties performed
in the last thirty years, the number of revision surgery is
growing constantly, particularly in elderly patients. PF are
significantly more common after revision surgery and may
be associated with poor bone quality, stress shielding, os-
teolysis and consequent bone loss. The incidence of PF af-
ter revision THAs ranges from 4 to 11%, and even up to
30% incidence is reported after knee revision surgery (3).
PF will have a deep impact in community health care re-
sources because are associated with higher rates of mor-
bidity and mortality. Toogood et al. reported results of a na-
tion-wide survey and they found that patients admitted to
hospital for revision surgery after PF ranged from 4.2 to
7.4% (7). The diagnosis disproportionately impacts women
and an older population, when compared to the other rea-
sons for revision (mechanical complication, infection, oste-
olysis, articular bearing surface wear, dislocation). Specifi-
cally, the mean age for the PF patients was 74.6 years and
9.6 years older than all other revisions as a combined
group. More often these patients have been admitted emer-
gently or urgently; they had longer hospitalization mean
time and higher mortality (7).
Drew et al. reviewed 291 patients treated for periprosthetic
femur fractures. They found out a mortality of 13.1% and of
15.8 % after 12 and 18 months, respectively. Furthermore,
patients have a chance of either death or reoperation at
one year of 24% (8). Bhattacharyya et al. compared one-
year mortality in three groups of different surgical treat-
ments:  hip fracture (16%), periprosthetic femoral fractures
(11%), primary THA and TKA (2.9%) (9). 
A retrospective review carried out by Zheng et al. showed
that even when appropriate surgical treatment is achieved,
patients with periprosthetic hip fracture could never obtain
a complete recovery and clinical outcomes are significantly
worse (10).
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Causes and risk factors 
As outlined above PF disproportionately impacts women
and elderly population (7). 
Most frequently, periprosthetic fracture is the result of low-
energy trauma, which has been shown to account for 75%
of fractures, in one report (11).
Signif icant comorbidit ies, osteoporosis/osteopenia,
rheumatoid arthritis (RA) and revision surgery are all con-
tributing factors (3). Osteopenia was described as a crucial
risk factor for 75% of cases (12) in humeral PFs. Other
studies showed that almost 50% of patient with humeral PF
had a diagnosis of RA (3). Platzer et al. (13) reported the
presence of severe osteoporosis or RA in 73% of patients
treated for distal femoral PF.
The evalutation of implants fixation and the prevention of
loosening are essential in order to reduce the risk of PFs.
Lindahl et al. suggest that routine radiographic follow-up in
patients with primary or revision THA is mandatory: in fact,
they found out that 51-66% patients had a loose stem at
the time of fracture (11). 
In several studies some intra-operative fractures deserved
special mention due to the difference in mechanism of in-
jury, risk factors and treatment. In total shoulder arthroplas-
ty risk factors involved are female sex, ASA (Classification
3 or 4) and diagnosis of post-traumatic arthritis (14). In revi-
sion hip arthroplasty, intra-operative femur fracture has an
incidence of 12% despite 1.7% of primary THA; risk factors
are: female sex, age over 65, cementless stems (5, 15).
They are often associated with bone and soft tissue defor-
mities as reported in case of THA for development dyspla-
sia of the hip (DDH) (16).  
Surgeon experience and a proper surgical technique can
influence the incidence of PF. In primary and revision THA
under-reaming of the acetabulum and a forceful femoral
preparation for stem insertion are commonly considered
risk factors for fractures. In shoulder arthroplasty excessive
external rotation of the humerus during the procedure must
be avoided (3). Major mistakes as femoral anterior notching
in total knee replacement have been proven to be associat-
ed in 10-46% of cases with supracondylar fractures (17)
even though some recent studies disproved that (3).
Several studies reported higher rates of fractures after ce-
mentless implants and press-fit techniques (4, 5, 18-20). A
review carried out by Abdel et al. point out that the femoral
intra-operative fractures occur 14 times more often when a
cementless stem is used for THA. Furthermore, post-opera-
tive fractures are 3 times more frequent with cementless
stems (5). Monoblock cups (18), elliptical cups (4) and ex-
treme proximal taper angle stems (20) have been shown to
be risk factors for PF. In TKA, the implant design influences
the type of resection from the intercondylar notch. So, the
relative risk for distal femoral fracture is 4.74 when compar-
ing a posterior-stabilized implant with a cruciate-retaining
implant (21). In TSA, no definitive conclusions could be
reached about the impact of implant design, technique for
preparation of the humerus and glenoid, and cemented vs
cementless implantation on PF incidence. 
Classification, management and results 
The principles of management of PF are basically founded
on the location of the fracture, the stability of the implant
and the amount of bone loss. Over the years PF affecting
every single anatomic joint have been evaluated by dozens
of different classifications (22-25) which represented a
slight adjustment of the previous and might become redun-
dant.
Of all the proposed classification systems for periprosthetic
fractures, the Vancouver Classification is the most widely
applied. It became widely accepted due to the significant
intra- and inter-observer reliability, and therefore because
offers an accurate tool for guiding therapeutic plans (26).
The Vancouver classification divides periprosthetic femoral
fractures into types A, B, and C and further categorizes
type A into two subtypes (AG and AL) and type B fractures
into three subtypes (B1, B2, and B3).
Duncan et al. in 2014 “incorporated what has been learnt
over the years into a New Unified Classification System
(UCS) covering the management of all periprosthetic frac-
tures” (27). They expand Vancouver Classification, include
three specific fractures types (D, E and F) and combined it
with AO/OTA fracture and dislocation Classification achiev-
ing an unique classification system (Table 1). 
The UCS has been tested in pelvic and femur fractures
proving a significant and substantial inter- and intra-observ-
er agreement (28), further studies are required to confirm it
and to test UCS in other joints. 
The decision making and results of PF treatment (Tables 1,
2, 3, 4) depends on fracture pattern, location and it is strict-
ly linked to characteristics of patients (age, daily activities,
expectations, comorbidities, quality of bone). 
According to UCS classification (27), Type A are fractures
of an aphophysis/protuberance of bone. According to the
functional role of soft tissues attached, treatment choice
changes: even if lesser trochanter of the femur and dis-
placed coracoids process of the scapula are treated con-
servatively, the greater tuberosity of the humerus, the su-
perior pole of patella, the tibial tuberosity and greater
trochanter instead require early operation.  
Type B fracture is located in the bed supporting or adjacent
to an implant and the sub-classification is equivalent to
Vancouver classification. 
Type B1 are fractures involving well fixed implants. The
treatment depends on fracture patterns and it is closely re-
lated to the bone segment involved; the management in-
cludes reduction and fixation using plates with cerclage and
screws (29-33). Several implants with different locking sys-
tems have been proposed in order to improve the fixation
of the fracture around or close to the stem: e.g. Dall-Miles
plates, Hook plates, Cable-ready system, Locking compres-
sion plates (LCP), Variable angle locking plate (VA-LCP),
Locking attachment plates (LAP). Stoeffel et al. in a sys-
tematic review of 1571 case of femoral PFs (70.4% Van-
couver type B1) found that close reduction and minimally
invasive plate osteosynthesis (MIPO) using locking com-
pression plates (LCP) had lower rates of nonunion and re-
fracture than open reduction and conventional plates
(nonunion: 0.0 vs 4.5%, p = 0.001; refracture: 0.6 vs 3.8%,
p = 0.024) (34).
Regarding periprosthetic distal femur fractures with stable
implant several options are allowed; Ristevski et al. (35), in
a systematic review providing a total of 719 fractures,
showed that locked plating and retrograde intramedullary
nailing offer significantly better results instead of conserva-
tive treatment and conventional plate; moreover, locking
plate showed lower rates of malunion compared to retro-
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grade intramedullary nail but demonstrated no significant
differences with regard to rates of nonunion (malunion: 7.6
vs 16.4%, p=0.02; nonunion: 8.8 vs 3.6%, p=0.05).
In contrast to fractures of the lower limb, humerus fractures
are mostly conservatively treated. Neviaser et al. stated
that periprosthetic humeral fractures with a well fixed im-
plant and acceptable alignment can be managed nonopera-
tively (36). Kurowicki et al. (37) treated a series of 7 humer-
al PF (type B according to Wright and Cofield classification)
using a locking plate with eccentrically placed screw holes;
they reported a 100% union rate and excellent pain relief
(mean visual analogic score of 0.5) at an average follow-up
of 29 weeks.  
In Type B2 fractures the implant is loose but bone stock is
preserved, and revision surgery is the preferred treatment
choice (27, 38-41). A Type B3 pattern is a B2 femoral frac-
ture with poor bone stock that might require complex recon-
struction or even a salvage procedure (megaprosthesis, al-
lograft/stem composite). Munro et al. reviewed, at a mean
follow-up of 54 months, 46 femoral PF Vancouver type B2
and B3 treated with modular tapered titanium stem. They
found stem subsidence in 24% of cases but acceptable
clinical results: Oxford score (76 of 100), WOMAC function
and pain scores (75 and 82 of 100) (38). Neumann et al.
reviewed 55 consecutive patients underwent revision
surgery using a modular cement-less stem for femoral type
B2/B3 fractures (39). The mean HHS postoperatively at 67
months’ follow-up was 72 points (range, 45-97) and com-
plete fracture union occurred in all patients three to six
months after surgery.
Rasouli et al. (42) reviewed published reports about Van-
couver type B3 femoral PFs and they recommended the
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Table 1 - UCS Classification and periprosthetic fractures treatment algorithm. 
JOINT  BONE  
I: Shoulder 
II: Elbow 
III: Wrist 
IV: Hip 
V: Knee 
VI: Ankle 
1: Humerus 
14: Glenoid/scapula 
2: Radius/ulna  
3: Femur 
4: Tibia  
34: Patella 
6: Acetabulum/pelvis 
7: Carpus/metacarpals 
8: Talus 
FRACTURE TYPE TREATMENT  
A 
Apophyseal or extraarticular/periarticular 
Subtypes 
  • A1: Avulsion of 
    (e.g. greater trochanter) 
  • A2: Avulsion of  
    (e.g. lesser trochanter) 
Depends on displacement and importance of soft tissue attached, e.g.:  
  • greater trochanter, tibial tuberosity, greater humeral tuberosity: surgical treatment 
  • lesser trochanter, coracoid process: conservative treatment 
B 
Bed of the implant or around the implant 
Subtypes 
  • B1: Prosthesis stable, good bone 
  • B2: Prosthesis loose, good bone 
  • B3: Prosthesis loose, poor bone or bone  
    defect 
 
 
 
B1: Lower limb: reduction and fixation, LCP and if possible MIPO technique preferred. 
B1: Upper limb: depends on displacement, conservative treatment preferred.   
B2: Revision surgery. 
B3: Revision surgery that may require complex reconstruction (megaprosthesis, 
allograft/stem composite). Depends on the bone loss and age/activity of the patients. 
C 
Clear of or distant to the implant 
Same management as no-periprosthetic fracture. 
D 
Dividing the bone between two implants 
or interprosthetic or intercalary 
Decision-making depends on “block-out analysis”*.  
 
Subtype A (both prostheses stable): reduction and fixation 
Subtype B (one stable and one loose): revision surgery  
Subtype C (both loose):both joint  revision surgery, total replacement 
E 
Each of two bones supporting one 
arthroplasty or polyperiprosthetic 
Decision-making depends on “block-out analysis”*  
(e.g. separate assessment of femoral fracture with stem of THA and acetabular fracture 
with cup) 
F 
Facing and articulating with a 
hemiarthroplasty 
 
Depends on displacement, conservative treatment preferred. 
*Block-out analysis= to analyze separately PF in relation with two joints. 
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use of allograft composite prosthesis in young and active
patients and proximal femoral replacement in older and
less active patients. In spite of the high rate of overall com-
plications with these two procedures, they reported accept-
able survivorship rates ranging from 74% to 89% at 2 to 15
years’ follow-up. Bhattacharyya et al. (9) showed that revi-
sion surgery (12%) in Vancouver type B fractures is associ-
ated with significant lower mortality ratio than ORIF (33%; p
<0.03).
Type C fracture is distal to the implant and can be treated
according to AO/OTA surgical fixation principles (27). 
Type D are also known as Interprosthetic fractures. The
correct preoperative planning involves the study of fracture
pattern of the two joint individually, the so-called “block-out
analysis”. Treatment is extremely variable (conservative,
ORIF, revision surgery of one or both joints involved) and
depends on stability of the implants. Three subtypes of in-
terprosthetic fractures have been described according to
Solarino et al. (43): subtype A (both prostheses stable),
subtype B (one stable and one loose), subtype C (both
loose). Platzer et al. reported results of 19 interprosthetic
femoral fractures with both stable implants, treated suc-
cessfully with ORIF; they found 86% fracture healing
achieved at 6 months, mean Harris Hip Score of 78.4
points and Knee injury and osteoarthritis outcome score of
71.8 points (44). 
Type E is a fracture of each of two bones supporting one
arthroplasty or polyperiprosthetic; the “block out analysis”
concept is the same required to be used in D fractures. 
Type F are fractures of a joint surface which is not re-
placed but is articulated with an implant (i.e. acetabulum or
glenoid in hemiarthroplasty, patella in TKA without patella
resurfacing). In Type F fractures decision-making is related
to implant displacement and conservative treatment is pre-
ferred when achievable.
Pharmacological treatment
Severe osteoporosis affects the majority of patients with a
PF. Furthermore, age, comorbidities and prolonged immo-
bilization, justify the long healing time, with higher non-
union and complications rates after PF.
Therefore, the “Diamond concept” for fracture healing,
should be taken in consideration in PF as well as in all oth-
er fragility fractures (45). According to this theory, the os-
teogenesis process in bone union, can be supported by the
implantation of mesenchymal stem cells, scaffolds and
growth factors in the fracture bed. Additionally, the surgical
procedure should provide the appropriate mechanical and
biological environment, the so-called “biological chamber”,
in order to efficiently enhance the physiological healing
process. The “Diamond Concept” has later evolved into the
“Pentagon Concept”, including adjuvant multiple systemic
pharmacological treatment (anti-resorptive and anabolic
drugs) as key-role therapy to enhance bone metabolism
(46).
Systemic treatment for fracture healing is described only in
small series with encouraging results, but large RCTs are
required in order to prove their validity (47).  
Kim et al. reported the use of teriparatide in challenging
cases as femoral PF, atypical fractures and nonunion (48).
In their series, the mean time to clinical union was recorded
as 5.7 months, and the median time to radiological union
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was recorded as 5.4 months. From 2009 we began to surgi-
cally treat femoral PF with ORIF or stem revision in associ-
ation with pharmacological anabolic treatment (teriparatide
or strontium ranelate) (49). The results at 2-year minimum
follow-up showed satisfying clinical results.  The mean HHS
score was 84 points (range, 76 - 88) with a mean 97.7° of
flexion (range, 90 - 100). All the patients achieved full
weight bearing at 3 months after surgery. The mean radio-
logical healing time was 4 months in patients treated with
ORIF and 3.5 months in patients who underwent stem revi-
sion surgery.
Conclusions
Despite all efforts periprosthetic fractures are still an emer-
gent problem associated to high rates of morbidity and
mortality. The prevention of PF through radiological surveil-
lance is crucial in order to detect early signs of implant
loosening and lack of stability. Moreover, other well known
risk factors, as osteoporosis, should be properly and pre-
ventively treated.
A comprehensive treatment algorithm should allow to fully
understand the personality of the fracture. Besides local
criteria (as location, stability and bone loss), PF treatment
options should be influenced by systemic factors as age of
the patient, activity level, bone metabolism and major/minor
comorbidities. In summary, the combination of mechanical
stability obtained by modern surgical techniques associated
with pharmacological systemic treatment seems to be the
path to take in the future. 
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